The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children
about
Off-label psychopharmacologic prescribing for children: history supports close clinical monitoringGeneralizing from clinical trial data: a case study. The risk of suicidality among pediatric antidepressant usersChanges in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental studyHow have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Suicidality and montelukast.Leveraging graph topology and semantic context for pharmacovigilance through twitter-streams.What are the policy implications of the evidence on cannabis and psychosis?Psychiatrists' attitudes towards autonomy, best interests and compulsory treatment in anorexia nervosa: a questionnaire survey.The drugs don't work? antidepressants and the current and future pharmacological management of depression.New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence?A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacksDo antidepressants really work?A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: a decision analysis model.Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.Depressive Disorders: Major Depressive Disorder and Persistent Depressive DisorderThe ethics of psychopharmacological research in legal minors
P2860
Q21202071-3A49EAE6-E4FC-4C98-A19F-AB48246DFAFAQ31151227-6F80A504-0115-41FE-B220-E8B404E5EBADQ33774659-891CB394-3B9B-4164-AA31-956843EC2708Q34575698-D59C8C1F-ABCD-4869-8921-5D31DF26103BQ34590507-16DC9DD4-9AC0-4349-89A0-57492F960128Q34608587-462F37F6-28E7-4001-AF73-D1D151E80DB6Q36170276-CA795A83-13AE-4427-964B-29B1F84A9F69Q36606248-9DEC49E2-9A12-4EFE-A45E-903B0BB4D556Q37040157-C691CC36-C87E-4B60-9D04-32EF878FAA47Q37079049-E42FEF52-0597-4647-A7CB-0326576F9089Q37157631-A8A92C62-8D6E-40C3-8486-E56A45AF48BDQ37574392-8352009B-5D77-46EA-A75C-69476FD19D0AQ38476909-AE275103-4534-4E3F-AB8A-5223FE432850Q42682469-BB8D49B0-4579-4FE1-971F-275682B857CDQ43072729-66DC38F4-DE9D-4FF8-AD8F-FB7427E45913Q44834340-0B19B7F4-6A2A-4343-B659-50D2BEA51CCCQ45279315-2AD76F24-FE17-4E78-9340-54AAC9DC925FQ46168219-10566ABC-53DC-4C16-8D11-58DE369C16B3Q57703141-F72AA251-1EB0-42C8-BA5B-7ED11E39C93BQ58670538-0BE43CC3-D283-4442-95F3-8140C3817CAA
P2860
The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The flawed basis for FDA post- ...... anti-depressants and children
@ast
The flawed basis for FDA post- ...... anti-depressants and children
@en
The flawed basis for FDA post- ...... anti-depressants and children
@nl
type
label
The flawed basis for FDA post- ...... anti-depressants and children
@ast
The flawed basis for FDA post- ...... anti-depressants and children
@en
The flawed basis for FDA post- ...... anti-depressants and children
@nl
prefLabel
The flawed basis for FDA post- ...... anti-depressants and children
@ast
The flawed basis for FDA post- ...... anti-depressants and children
@en
The flawed basis for FDA post- ...... anti-depressants and children
@nl
P2860
P3181
P356
P1476
The flawed basis for FDA post- ...... anti-depressants and children
@en
P2093
Donald F Klein
P2860
P2888
P304
P3181
P356
10.1038/SJ.NPP.1300996
P407
P577
2006-04-01T00:00:00Z
P5875
P6179
1020944227